We pooled and analyzed the genetic information of 693 glioma patient samples from the CGGA database (Figure 5A) and found that the mutation rates of EMP3 and CHI3L1 were 1% and 1.2% in 693 patients. This evidence concerns the gene CHI3L1 and central nervous system cancer.